O12. Survival of patients with advanced EGFR-mutated NSCLC treated with EGFR TKIS in routine clinical practice

BACKGROUND: The use of epidermal growth factor receptor (EGFR) TKIs in EGFR-mutated non-small cell lung cancer (NSCLC) moved the survival boundary for these patients up to impressive 19 to 35 months, as reported in seven randomized clinical trials (RCTs). In addition, latest results of RCTs show sig...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Transl Lung Cancer Res
Egile Nagusiak: Hitij, Nina Turnsek, Sadikov, Aleksander, Knez, Lea, Mohorcic, Katja, Jakelj, Andraz, Cufer, Tanja
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Pioneer Bioscience Publishing Company 2014
Gaiak:
CELCC 2014 Abstracts
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4367788/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2014.AB011
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak